USP22 Promotes Therapeutic Resistance to Prostate Cancer by Deubiquitinating Myc Leading to Increased Myc Regulated Oncogenic Cell Transformation

Ryan Liu

2022

Abstract

Prostate cancer is the second most common and deadly type of cancer in developed countries. Increasing evidence has shown the deregulation of the UPS22 deubiquitinase, a protease that cleaves ubiquitin from proteins to cancer development. USP22 is a promoter of the tumor phenotype by modulating nuclear receptor, a ligand-regulated transcription factor, and oncogenic signaling, networks of signaling pathways that interact with each other to control the growth and progression of a tumor. Since USP22 promotes therapeutic resistance to prostate cancer, there is a deceleration in cell apoptosis.

Download


Paper Citation


in Harvard Style

Liu R. (2022). USP22 Promotes Therapeutic Resistance to Prostate Cancer by Deubiquitinating Myc Leading to Increased Myc Regulated Oncogenic Cell Transformation. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 702-706. DOI: 10.5220/0011260300003443


in Bibtex Style

@conference{icbeb22,
author={Ryan Liu},
title={USP22 Promotes Therapeutic Resistance to Prostate Cancer by Deubiquitinating Myc Leading to Increased Myc Regulated Oncogenic Cell Transformation},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={702-706},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011260300003443},
isbn={978-989-758-595-1},
}


in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - USP22 Promotes Therapeutic Resistance to Prostate Cancer by Deubiquitinating Myc Leading to Increased Myc Regulated Oncogenic Cell Transformation
SN - 978-989-758-595-1
AU - Liu R.
PY - 2022
SP - 702
EP - 706
DO - 10.5220/0011260300003443